← Leaderboards
Ricardo Mouro Pinto
Massachusetts General Hospital
$1,596,958
Attributed
$1,596,958
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.7M · FY2022–25$5M$3.8M$2.5M$1.3M$0
'22
'23
'24
'25
Funding mix
By agency
NIH$14,392,214 · 2
By mechanism
U19$12,795,256 · 1
R01$1,596,958 · 1
Top collaborators
- Mandana Arbab3 shared
- Steven J Gray3 shared
- David R Liu3 shared
- Cathleen M Lutz3 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- David T Scadden$62,181,067
- Shengdar Tsai$7,312,012
- J. Keith Joung$24,183,955
- Howard L Liber$3,228,829
- Nir Hacohen$29,379,938
Others in their field
Other Rising Stars on “Effective Therapy”
- Supriya Menezes · The Emmes Company, Llc$18,394,958
- Daniel Hunter Reirden · Westat, Inc.$15,038,020
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Maximilian Haeussler · University Of California Santa Cruz$12,592,563
- Benjamin M Greenberg · Ut Southwestern Medical Center$11,474,975
- Eric Anderson · Columbia University Health Sciences$11,474,975
Research focus
Effective TherapyGenesMouse ModelValidationNeuronsHuntington DiseaseGeneticIn VivoPathway InteractionsTranslatingTissuesPhenotypeBase EditorCellsFriedreich AtaxiaCag RepeatBrainDrug TargetingBiopsyClinical PhenotypeBiological MarkersAllelesDisease ProgressionAntisense Oligonucleotides
Grant awards (7)
Preclinical Genome Editing for Rare Neurological Diseases$4,319,346
U19 · FY2025 · NS
Somatic Repeat Expansions as a Therapeutic Target for Trinucleotide Repeat Disorders$371,076
R01 · FY2025 · NS · contact PI
Preclinical Genome Editing for Rare Neurological Diseases$4,213,908
U19 · FY2024 · NS
Somatic Repeat Expansions as a Therapeutic Target for Trinucleotide Repeat Disorders$400,178
R01 · FY2024 · NS · contact PI
Preclinical Genome Editing for Rare Neurological Diseases$4,262,002
U19 · FY2023 · NS
Somatic Repeat Expansions as a Therapeutic Target for Trinucleotide Repeat Disorders$412,753
R01 · FY2023 · NS · contact PI
Somatic repeat expansions as a therapeutic target for trinucleotide repeat disorders$412,951
R01 · FY2022 · NS · contact PI